Sulindac capsule and preparation method thereof

By optimizing the wet granulation process and selecting excipients, and by using sodium dodecyl sulfate, the problems of low dissolution and poor wettability in the preparation of sulindac capsules were solved, achieving a dissolution profile similar to the reference formulation and a simplified production process.

CN118903039AInactive Publication Date: 2024-11-08NINGBO DAHONGYING PHARM CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411011010.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing preparation process for sulindac capsules has problems such as high particle viscosity and low dissolution during wet granulation, long drying time and low efficiency, and poor particle wettability leading to poor dissolution.

Method used

Wet granulation is performed using water as a wetting agent, and sodium dodecyl sulfate, a surfactant, is used to increase the wettability of the particles. The wet granulation process is optimized through a fluidized bed drying process, and suitable excipients such as microcrystalline cellulose and starch are selected to avoid the problem of low dissolution caused by binders.

Benefits of technology

The dissolution profile of sulindac capsules in pH 4.0 + 0.3% SDS medium was improved to be consistent with the reference formulation, simplifying the preparation process, reducing manual operation, and enhancing the wettability of the particles.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903039A_ABST
    Figure CN118903039A_ABST
Patent Text Reader

Abstract

The invention discloses a sulindac capsule and a preparation method thereof. The preparation method comprises the following steps: weighing, mixing 1, wet granulation, wet size stabilization, drying, dry size stabilization, mixing 2, total mixing, capsule filling and packaging. According to the invention, by selecting proper auxiliary materials, the requirements of a sulindac preparation process are met; according to the invention, water is used as a wetting agent for wet granulation to obtain sulindac particles with proper particle size and moderate viscosity; the surfactant lauryl sodium sulfate is used for increasing the wettability of particles and improving in-vitro dissolution, and the paddle method 75rpm dissolution curve of the obtained sulindac capsule in an SDS medium with the pH being 4.0 + 0.3% is consistent with that of a reference preparation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of pharmaceutical manufacturing, and in particular to a sulindac capsule and a preparation method thereof. Background Art

[0002] Sulindac is a nonsteroidal anti-inflammatory drug (NSIA) of the aryl alkanoic acid class. Sulindac is a prodrug and has no biological activity itself. Through oral absorption, sulindac is converted into reversibly reduced sulfide (related to biological activity) and irreversible sulfide (inactive) by liver enzymes in the body. The active sulfide can inhibit cyclooxygenase and the synthesis of prostaglandins, thus having anti-inflammatory and analgesic effects. Sulfide enters the enterohepatic circulation and is reoxidized to inactive sulindac in the kidney tissue, and is eventually excreted in the feces and urine in the form of the original drug, inactive metabolites or glucuronic acid conjugates. At the same dose, the anti-acute inflammatory effect of sulindac is equivalent to that of ibuprofen, which is 0.3 to 0.5 times that of indomethacin; the anti-protein edema effect is 16 times that of aspirin, and the analgesic effect is equivalent to that of indomethacin, which is ten times that of ibuprofen. Sulindac does not inhibit prostaglandin synthase, and its active sulfur metabolites inhibit prostaglandin synthase by only 0.2 times that of indomethacin. In patients with arthritis, sulindac is 12 times more effective than aspirin, and the incidence of overall adverse reactions, mild gastrointestinal reactions, and tinnitus is lower than that of patients taking aspirin. In patients with ankylosing spondylitis, the efficacy of taking sulindac 300-400 mg / day is equivalent to that of phenylbutazone 400-600 mg / day, and its durability is better than that of phenylbutazone.

[0003] The original preparation process of sulindac capsules is to wet mix sulindac with other excipients, use hypromellose as a binder, dry the wet granules in an oven after wet granulation, and then fill the capsules after granulation. The wet granulation process has the following problems:

[0004] (1) The binder is hypromellose, the granules obtained are very sticky, the dissolution is low, and the dissolution curve in pH 4.0 + 0.3% SDS medium is not similar to that of the reference preparation;

[0005] (2) The wet granules are dried in an oven, which takes a long time and requires manual turning, resulting in low efficiency;

[0006] (3) The prepared particles have poor wettability and will float on the water surface, which may lead to low dissolution due to insufficient wettability. Summary of the invention

[0007] The technical problem to be solved by the present invention is to overcome the technical defects of the background technology, and provide a sulindac capsule and a preparation method thereof. The present invention meets the requirements of the sulindac preparation process by selecting suitable excipients; the present invention uses water as a wetting agent for wet granulation to obtain sulindac particles with suitable particle size and moderate viscosity; the present invention uses a surfactant, sodium dodecyl sulfate, to increase the wettability of the particles and improve in vitro dissolution, and the obtained sulindac capsule has a paddle method 75rpm dissolution curve in a pH 4.0+0.3% SDS medium that is consistent with the reference preparation.

[0008] The technical solution adopted by the present invention to solve the above technical problems is as follows:

[0009] A method for preparing sulindac capsules comprises the following steps: weighing → mixing 1 → wet granulation → wet granulation → drying → dry granulation → mixing 2 → total mixing → capsule filling → packaging:

[0010] (1) Weighing: Weigh the raw materials and excipients according to the prescription amount of each sulindac capsule, namely, 100 mg of sulindac, 30-70 mg of microcrystalline cellulose, 0.2-40 mg of starch, 0.17-1.51 mg of sodium lauryl sulfate, and 0.5-1.0 mg of magnesium stearate, and set aside;

[0011] (2) Mixing 1: Add all the sulindac, microcrystalline cellulose, and starch from step (1) into a wet granulator and mix;

[0012] (3) Wet granulation: Start stirring, spray purified water, start shearing knife, granulate, obtain material a, and set aside;

[0013] (4) Wet granulation: the material a in step (3) is sieved to obtain material b for later use;

[0014] (5) Drying: subjecting the material b described in step (4) to boiling drying to obtain material c for later use;

[0015] (6) Dry granulation: The material c in step (5) is dry granulated using a sieve to obtain material d for later use;

[0016] (7) Mixing 2: Add the material d in step (6) and all the sodium dodecyl sulfate in step (1) into a mixer and mix them evenly to obtain material e for later use;

[0017] (8) Total mixing: uniformly mixing the material e in step (7) and all the magnesium stearate in step (1) in a mixer to obtain material f for later use;

[0018] (9) Capsule canning: the material f described in step (8) is capsule canned to obtain capsules;

[0019] (10) Packaging: Packaging the capsules described in step (9) to obtain the product.

[0020] Preferably, in step (1), raw materials and auxiliary materials are weighed according to the prescription amount of each sulindac capsule, namely 100 mg of sulindac, 32.52-66.12 mg of microcrystalline cellulose, 0.2-33.80 mg of starch, 0.17-1.51 mg of sodium lauryl sulfate, and 0.84 mg of magnesium stearate, and set aside.

[0021] Preferably, in step (1), the microcrystalline cellulose is microcrystalline cellulose PH101.

[0022] Preferably, in step (1), the starch is pregelatinized starch.

[0023] Preferably, in step (2), the rotation speed during mixing is 150 to 250 rpm, and the mixing time is 1 to 10 min.

[0024] More preferably, in step (2), the rotation speed during mixing is 200 rpm and the mixing time is 5 min.

[0025] Preferably, in step (3), the stirring speed is 150-250 rpm, the shearing speed of the shearing knife is 800-2000 rpm, the amount of water added is 70-130 mg / granule, and the granulation time is 0.5-5 min; the amount of water added is more preferably 80-95 mg / granule.

[0026] More preferably, in step (3), the rotation speed during stirring is 200 rpm, the shearing speed of the shearing knife is 1500 rpm, the amount of water added is 95 mg / granule, and the granulation time is 1 min.

[0027] Preferably, in step (4), the mesh size of the sieve is 4 to 24 meshes.

[0028] Preferably, in step (4), the screen is made of nylon or stainless steel.

[0029] Preferably, in step (5), the air inlet temperature during drying is 60-85° C., and the loss on drying LOD is ≤3%.

[0030] Preferably, in step (6), the pore size of the sieve is 0.8 to 2.0 mm.

[0031] More preferably, in step (6), the pore size of the sieve is 1.0 mm.

[0032] Preferably, in step (6), the screen is made of stainless steel.

[0033] Preferably, in step (7), the mixing time is 1 to 20 minutes.

[0034] More preferably, in step (7), the mixing time is 10 minutes.

[0035] Preferably, in step (8), the mixing time is 1 to 20 minutes.

[0036] Preferably, in step (10), the packaging is aluminum-plastic packaging.

[0037] A sulindac capsule. According to the prescription amount, the formula of each sulindac capsule includes 100 mg of sulindac, 30-70 mg of microcrystalline cellulose, 0.2-40 mg of starch, 0.17-1.51 mg of sodium lauryl sulfate, and 0.5-1.0 mg of magnesium stearate; according to the prescription amount, the total content of each sulindac capsule is 130.87-212.51 mg.

[0038] More preferably, according to the prescription amount, the formula of each sulindac capsule includes 100 mg of sulindac, 32.52-66.12 mg of microcrystalline cellulose, 0.2-33.80 mg of starch, 0.17-1.51 mg of sodium lauryl sulfate, and 0.84 mg of magnesium stearate; according to the prescription amount, the total content of each sulindac capsule is 133.73-202.27 mg.

[0039] A sulindac capsule comprises the following raw and auxiliary materials: 100 mg of sulindac, 30-70 mg of microcrystalline cellulose, 0.2-40 mg of starch, 0.17-1.51 mg of sodium lauryl sulfate and 0.5-1.0 mg of magnesium stearate.

[0040] More preferably, the raw material and auxiliary material composition of the sulindac capsule prescription is: 100 mg of sulindac, 32.52-66.12 mg of microcrystalline cellulose, 0.2-33.80 mg of starch, 0.17-1.51 mg of sodium lauryl sulfate, and 0.84 mg of magnesium stearate.

[0041] In the above technical solution, the microcrystalline cellulose is a filler.

[0042] In the above technical solution, the starch is a disintegrant.

[0043] In the above technical solution, the sodium dodecyl sulfate is a surfactant.

[0044] In the above technical solution, the magnesium stearate is a lubricant.

[0045] In the above technical solution, the water is a wetting agent.

[0046] Basic principles of the present invention:

[0047] The technical solution provided by the present invention is to improve the dissolution rate of sulindac capsule preparation. The particles in sulindac capsules are obtained by direct canning of powder particles without tableting process. Since the specific surface area of ​​powder particles is larger, their wettability is not as good as tablets. In addition, since the capsule itself is not as good as tablets, the capsule dissolution is slower than tablets, and the absorption may be slow in vivo due to wettability problems. The present invention uses a wet granulation process, optimizes the process of preparing adhesive solution by screening the types and models of auxiliary materials, and avoids the problem that the dissolution curve of sulindac capsule is low due to the high viscosity of the adhesive solution in the original prescription; by adding the surfactant sodium dodecyl sulfate, the lipophilic and hydrophilic characteristics of sodium dodecyl sulfate are utilized to reduce the surface tension of powder particles and dissolution medium, increase the wettability of particles in dissolution medium after sulindac capsules are broken, and ensure that the dissolution curve of sulindac capsules is similar to that of reference.

[0048] Compared with the prior art, the present invention has the following beneficial effects:

[0049] (1) The present invention simplifies the trouble caused by the slurry preparation process by optimizing the wet granulation process and using purified water for granulation; at the same time, it avoids the problem of the granules being agglomerated due to the adhesive and the low dissolution;

[0050] (2) The present invention uses a boiling drying process, which reduces the trouble caused by manual operation;

[0051] (3) The present invention increases the wettability of the particles by adding sodium lauryl sulfate, so that the dissolution curve of sulindac capsules is consistent with that of the reference preparation. BRIEF DESCRIPTION OF THE DRAWINGS

[0052] Figure 1 This is a comparison chart of the dissolution effects of sulindac capsules prepared in Examples 1 to 10 of the present invention and Comparative Example 1. DETAILED DESCRIPTION

[0053] In order to better understand the content of the present invention, further description is given below in conjunction with specific embodiments and accompanying drawings. It should be understood that these embodiments are only used to further illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that after reading the content described in the present invention, those skilled in the art may make some non-essential changes or adjustments to the present invention, which still belong to the protection scope of the present invention.

[0054] Example 1

[0055] A method for preparing sulindac capsules, comprising the following steps:

[0056] (1) Weighing: Weigh the raw materials and excipients according to the prescription amount of 1000 sulindac capsules, namely 100 g of sulindac, 9.32 g of microcrystalline cellulose PH1014, 17.00 g of pregelatinized starch, 0.84 g of sodium lauryl sulfate, and 0.84 g of magnesium stearate, and set aside;

[0057] (2) Mixing 1: Add all the sulindac, microcrystalline cellulose PH101, and pregelatinized starch from step (1) into a wet granulator and mix for 3 min at a speed of 200 rpm;

[0058] (3) Wet granulation: Start stirring at 200 rpm, spray in 88 g of purified water, then start the shearing knife at 1500 rpm, granulate for 1 min, and obtain material a for later use;

[0059] (4) Wet granulation: Pass the material a described in step (3) through a 10-mesh stainless steel sieve for wet granulation to obtain material b for later use;

[0060] (5) Drying: subjecting the material b described in step (4) to boiling drying at an air inlet temperature of 75° C. until the moisture content is less than 3.0%, to obtain material c, which is set aside;

[0061] (6) Dry granulation: The material c in step (5) is dry granulated using a 1.0 mm stainless steel sieve to obtain material d for later use;

[0062] (7) Mixing 2: Add the material d in step (6) and all the sodium dodecyl sulfate in step (1) into a mixer and mix for 10 minutes to obtain material e, which is set aside;

[0063] (8) Total mixing: Mix the material e in step (7) and all the magnesium stearate in step (1) in a mixer for 5 min to obtain material f for later use;

[0064] (9) Capsule filling: The material f described in step (8) is capsule filled, and No. 3 capsules are used for capsule filling to obtain capsules;

[0065] (10) Packaging: The capsules described in step (9) are packaged in aluminum-plastic packaging.

[0066] Example 2

[0067] This example is substantially the same as Example 1, except that 49.32 g of microcrystalline cellulose PH101 and 17.00 g of pregelatinized starch in step (1) of Example 1 are replaced with 66.12 g of microcrystalline cellulose PH101 and 0.20 g of pregelatinized starch, respectively.

[0068] Example 3

[0069] This example is substantially the same as Example 1, except that 49.32 g of microcrystalline cellulose PH101 and 17.00 g of pregelatinized starch in step (1) of Example 1 are replaced with 32.52 g of microcrystalline cellulose PH101 and 33.80 g of pregelatinized starch, respectively.

[0070] Example 4

[0071] This example is substantially the same as Example 1, except that 149.32 g of microcrystalline cellulose PH10 and 0.84 g of sodium lauryl sulfate in step (1) of Example 1 are replaced with 148.65 g of microcrystalline cellulose PH10 and 1.51 g of sodium lauryl sulfate, respectively.

[0072] Example 5

[0073] This example is substantially the same as Example 1, except that 149.32 g of microcrystalline cellulose PH10 and 0.84 g of sodium lauryl sulfate in step (1) of Example 1 are replaced with 149.99 g of microcrystalline cellulose PH10 and 0.17 g of sodium lauryl sulfate, respectively.

[0074] Example 6

[0075] This embodiment is substantially the same as Embodiment 1, except that the 1.0 mm stainless steel mesh in step (6) of Embodiment 1 is replaced with a 1.5 mm stainless steel mesh.

[0076] Example 7

[0077] This embodiment is basically the same as the embodiment 1, except that the step (3) of spraying purified water in the embodiment 1 is changed to spraying purified water 93 g.

[0078] Example 8

[0079] This embodiment is basically the same as Embodiment 1, except that the step (3) of spraying 88 g of purified water in Embodiment 1 is changed to spraying 83 g of purified water.

[0080] Example 9

[0081] This embodiment is basically the same as embodiment 1, with the only difference being that the stirring at 200 rpm, 88 g of purified water sprayed in, and the shearing knife turned on at 1500 rpm in step (3) of embodiment 1 is changed to stirring at 230 rpm, 88 g of purified water sprayed in, and the shearing knife turned on at 1800 rpm.

[0082] Example 10

[0083] This embodiment is basically the same as Embodiment 1, with the only difference being that the stirring at 200 rpm, 88 g of purified water sprayed in, and the shearing knife turned on at 1500 rpm in step (3) of Embodiment 1 is changed to stirring at 170 rpm, 88 g of purified water sprayed in, and the shearing knife turned on at 1200 rpm.

[0084] Comparative Example 1

[0085] A method for preparing sulindac capsules, comprising the following steps:

[0086] (1) Weighing: Weigh the raw materials and excipients according to the prescription amount of 1000 sulindac capsules, namely 100 g of sulindac, 11.20 g of microcrystalline cellulose PH101, 0.40 g of hypromellose, 1.20 g of sodium starch glycolate (internal addition), 1.80 g of sodium starch glycolate (external addition), and 3.30 g of magnesium stearate, and set aside;

[0087] (2) Slurry preparation: dissolve all the HPMC in step (1) in purified water to prepare 34 g of binder solution;

[0088] (3) Mixing 1: Add all the sulindac, microcrystalline cellulose PH101, and sodium starch glycolate (added internally) in step (1) into a wet granulator and mix for 3 min at a speed of 200 rpm;

[0089] (4) Wet granulation: Start stirring at 200 rpm, spray in 34 g of binder solution, then start shearing at 1500 rpm, granulate for 1 min, and obtain material a for later use;

[0090] (5) Wet granulation: Pass the material a described in step (4) through a 10-mesh stainless steel sieve for wet granulation to obtain material b for later use;

[0091] (6) Drying: drying the material b in step (5) in an oven at 75° C. until the moisture content is less than 3.0%, to obtain material c for later use;

[0092] (7) Dry granulation: The material c in step (6) is dry granulated using a 1.0 mm stainless steel sieve to obtain material d for later use;

[0093] (8) Mixing 2: Add the material d described in step (7) and all the sodium carboxymethyl starch (added) in step (1) into a mixer and mix for 10 minutes to obtain material e, which is set aside;

[0094] (9) Total mixing: Mix the material e in step (8) and all the magnesium stearate in step (1) in a mixer for 5 min to obtain material f, which is set aside;

[0095] (10) Capsule filling: The material f described in step (9) is capsule filled, and No. 3 capsules are used for capsule filling to obtain capsules;

[0096] (11) Packaging: The capsules described in step (10) are packaged in aluminum-plastic packaging.

[0097] Effect evaluation experiment

[0098] Dissolution determination: The compositions (capsules) obtained in Examples 1 to 10 and Comparative Example 1 were compared in vitro with the reference preparation (batch number: 0239A241, manufacturer: WATSON). Dissolution curve method: paddle method; dissolution medium: pH 4.0 + 0.3% SDS medium; dissolution volume: 900 ml; rotation speed: 75 rpm; absorption wavelength: 327 nm; sampling time: 5 min, 10 min, 15 min, 30 min, 45 min, 60 min, 90 min, 120 min.

[0099] The comparative table and graph of dissolution effects of sulindac capsules prepared in Examples 1 to 10 of the present invention and Comparative Example 1 are shown in Tables 1 and Figure 1 .

[0100] Table 1 Comparison of dissolution effects of sulindac capsules prepared in Examples 1 to 10 of the present invention and Comparative Example 1

[0101]

[0102] Note: f2 represents the similarity factor with the reference preparation, which is calculated at time points of 5min, 10min, 15min, 30min, 45min, 60min, 90min, and 120min. If f2 is greater than 50, it indicates that the dissolution condition is similar to that of the reference preparation in vitro.

[0103] From Table 1 and Figure 1 It can be seen that compared with Comparative Example 1, the dissolution performance of the compositions (capsules) prepared in Examples 1 to 10 is better, and f2 is greater than 50, which is similar to the reference preparation; among them, the composition (capsule) prepared in Example 5 has the highest similarity to the reference preparation.

[0104] The above dissolution experiment shows that, compared with the prior art sulindac capsule preparation prescription process, the sulindac capsule prepared by the present invention shows excellent product quality, which is a significant improvement over the prior art.

[0105] The technical solution provided by the present invention is to improve the dissolution rate of sulindac capsule preparation. The particles in sulindac capsules are obtained by direct canning of powder particles without tableting process. Since the specific surface area of ​​powder particles is larger, their wettability is not as good as tablets. In addition, since the capsule itself is not as good as tablets, the capsule dissolution is slower than tablets, and the absorption may be slow in vivo due to wettability problems. The present invention uses a wet granulation process, optimizes the process of preparing adhesive solution by screening the types and models of auxiliary materials, and avoids the problem that the dissolution curve of sulindac capsule is low due to the high viscosity of the adhesive solution in the original prescription; by adding the surfactant sodium dodecyl sulfate, the lipophilic and hydrophilic characteristics of sodium dodecyl sulfate are utilized to reduce the surface tension of powder particles and dissolution medium, increase the wettability of particles in dissolution medium after sulindac capsules are broken, and ensure that the dissolution curve of sulindac capsules is similar to that of reference.

[0106] Compared with the prior art, the present invention has the following beneficial effects:

[0107] (1) The present invention simplifies the trouble caused by the slurry preparation process by optimizing the wet granulation process and using purified water for granulation; at the same time, it avoids the problem of the granules being agglomerated due to the adhesive and the low dissolution;

[0108] (2) The present invention uses a boiling drying process, which reduces the trouble caused by manual operation;

[0109] (3) The present invention increases the wettability of the particles by adding sodium lauryl sulfate, so that the dissolution curve of sulindac capsules is consistent with that of the reference preparation.

[0110] The above description is not intended to limit the present invention, and the present invention is not limited to the above examples. Any changes, modifications, additions or substitutions made by a person skilled in the art within the spirit and scope of the present invention shall also fall within the protection scope of the present invention.

Claims

1. A method for preparing sulindac capsules, characterized in that: The steps include: (1) Weighing: Weigh the raw materials and excipients according to the prescription amount of each sulindac capsule, namely, 100 mg of sulindac, 30-70 mg of microcrystalline cellulose, 0.2-40 mg of starch, 0.17-1.51 mg of sodium lauryl sulfate, and 0.5-1.0 mg of magnesium stearate, and set aside; (2) Mixing 1: Add all the sulindac, microcrystalline cellulose, and starch from step (1) into a wet granulator and mix; (3) Wet granulation: Start stirring, spray purified water, start shearing knife, granulate, obtain material a, and set aside; (4) Wet granulation: sieve the material a in step (3) to obtain material b for later use; (5) Drying: subjecting the material b described in step (4) to boiling drying to obtain material c for later use; (6) Dry granulation: The material c in step (5) is dry granulated using a sieve to obtain material d for later use; (7) Mixing 2: Add the material d in step (6) and all the sodium dodecyl sulfate in step (1) into a mixer and mix them evenly to obtain material e for later use; (8) Total mixing: uniformly mixing the material e in step (7) and all the magnesium stearate in step (1) in a mixer to obtain material f for later use; (9) Capsule canning: the material f described in step (8) is capsule canned to obtain capsules; (10) Packaging: Packaging the capsules described in step (9) to obtain the product.

2. The method for preparing sulindac capsules according to claim 1, wherein: In step (1), the microcrystalline cellulose is microcrystalline cellulose PH101.

3. The method for preparing sulindac capsules according to claim 1, characterized in that: In step (1), the starch is pregelatinized starch.

4. The method for preparing sulindac capsules according to claim 1, characterized in that: In step (2), the rotation speed during mixing is 150-250 rpm, and the mixing time is 1-10 min; in step (3), the rotation speed during stirring is 150-250 rpm, the shearing speed of the shearing knife is 800-2000 rpm, the amount of water added is 70-130 mg / granule, and the granulation time is 0.5-5 min.

5. The method for preparing sulindac capsules according to claim 1, characterized in that: In step (4), the mesh size of the sieve is 4 to 24 meshes.

6. The method for preparing sulindac capsules according to claim 1, characterized in that: In step (5), the air inlet temperature during drying is 60-85° C., and the loss on drying LOD is ≤3%.

7. The method for preparing sulindac capsules according to claim 1, characterized in that: In step (6), the pore size of the sieve is 0.8 to 2.0 mm.

8. The method for preparing sulindac capsules according to claim 1, characterized in that: In step (7), the mixing time is 1 to 20 minutes; in step (8), the mixing time is 1 to 20 minutes.

9. A sulindac capsule, characterized in that: According to the prescription quantity, the formula of each sulindac capsule includes 100 mg of sulindac, 30-70 mg of microcrystalline cellulose, 0.2-40 mg of starch, 0.17-1.51 mg of sodium lauryl sulfate, and 0.5-1.0 mg of magnesium stearate; according to the prescription quantity, the total content of each sulindac capsule is 130.87-212.51 mg.

10. A sulindac capsule, characterized in that: The raw and auxiliary materials of the sulindac capsule prescription are as follows: 100 mg of sulindac, 30-70 mg of microcrystalline cellulose, 0.2-40 mg of starch, 0.17-1.51 mg of sodium lauryl sulfate, and 0.5-1.0 mg of magnesium stearate.

Citation Information

Patent Citations

  • Sulindac tablet composition as well as preparation method and application thereof

    CN117017932A